- Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of glabellar lines in the Fall of 2019, as previously announced - NEWARK, Calif.

  NEWARK, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at

  NEWARK, Calif. --(BUSINESS WIRE)--Sep. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare

NEWARK, Calif. --(BUSINESS WIRE)--Sep. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan Stanley 17th Annual Global

NEWARK, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare

- Conference call and webcast today at 4:30 p.m. ET - NEWARK, Calif. --(BUSINESS WIRE)--Aug. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the

Conference Call Scheduled for Monday, August 5, 2019 at 4:30 p.m. ET NEWARK, Calif. --(BUSINESS WIRE)--Jul. 29, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the

- Nolet will serve as Chair of the Audit Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jul. 17, 2019-- ​ Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today

- Beraud will also chair newly-formed Brand Strategy Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic

NEWARK, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual